As Celgene Corp (CELG) Shares Declined, Shareholder Cannell Peter B & Company INC Increased Its Stake by $6.95 Million

May 16, 2018 - By Lisa Delgado

Celgene Corporation (NASDAQ:CELG) Corporate LogoBig Money Sentiment decreased to 0.83 in 2017 Q4. It has change of 0.34, from 2017Q3’s 1.17. The ratio dropped due to CELG positioning: 156 sold and 478 reduced. 118 funds took holdings and 411 increased holdings. Investors holded 603.99 million in 2017Q3 but now own 561.38 million shares or 7.06% less. Calamos Wealth Management Limited Liability Corp holds 0.25% in Celgene Corporation (NASDAQ:CELG) or 18,314 shs. Cim Investment Mangement Inc stated it has 5,645 shs or 0.2% of all its holdings. Hbk Sorce Advisory Lc has 0.18% invested in Celgene Corporation (NASDAQ:CELG) for 14,681 shs. Moreover, Ferguson Wellman Cap has 0.02% invested in Celgene Corporation (NASDAQ:CELG). 149,639 were reported by Los Angeles Management And Equity Rech. Heritage Investors Mngmt invested in 0.14% or 22,810 shs. Inverness Counsel Limited Liability New York stated it has 1.13% in Celgene Corporation (NASDAQ:CELG). South Dakota Investment Council owns 0.49% invested in Celgene Corporation (NASDAQ:CELG) for 213,740 shs. Brave Asset has 39,416 shs for 2.14% of their capital. Product Prns Lc invested 0.57% in Celgene Corporation (NASDAQ:CELG). Barclays Public Limited Co holds 0.11% of its capital in Celgene Corporation (NASDAQ:CELG) for 1.29 million shs. Jolley Asset Mngmt Limited Com has 524 shs for 0.04% of their capital. Tanaka Capital Management reported 7,087 shs. Fukoku Mutual Life Insurance Comm owns 4,500 shs or 0.07% of their US capital. Mcrae Capital Mgmt stated it has 4.98% of its capital in Celgene Corporation (NASDAQ:CELG).

CELG registered $3.58 million net activity with 1 buying transaction and 3 insider sales since February 8, 2018. Another trade for 9,250 shs valued at $851,093 was sold by LOUGHLIN JAMES J. Another trade for 13,370 shs valued at $1.26M was sold by MARIO ERNEST. On Thursday, February 15 KAPLAN GILLA also sold $1.77 million worth of Celgene Corporation (NASDAQ:CELG).

In 2017Q4 Securities and Exchange form is reported J. Carlo Cannell’s holdings in Celgene Corp (CELG) which was rose by 4.42%. 66,820 shares were bought by Cannell Peter B & Company Inc as the company’s stock declined 19.30% with the market. The major pharmaceuticals company at the end of 2017Q4 was valued at $164.82M. It’s up from 1.51 million at the end of the previous reported quarter. Now it had 1.58 million shares held by the hedge fund run by J. Carlo Cannell. $59.52B is the MC of Celgene Corp. CELG is reaching $81.95 during the last trading session, after decreased 0.04%.Currently Celgene Corporation is downtrending after 31.28% change in last May 16, 2017. CELG has also 3.81 million shares volume. CELG underperformed the S&P500 by 42.83%.

About $3.77 billion and $2.91B US Long portfolio Cannell Peter B & Company Inc manages. According to a filing the fund reduced its stake in Ball Corp (NYSE:BLL) by 292,493 shares to 499,027 shares, valued at $18.89M in 2017Q4. Cannell Peter B & Company Inc has cut its stake in Hca Healthcare Inc (NYSE:HCA) and also reduced its holding in Hd Supply Holdings Inc (NASDAQ:HDS) by 120,097 shares in the quarter, for a total of 1.78M shares.

For more Celgene Corporation (NASDAQ:CELG) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Fool.com, Prnewswire.com or Seekingalpha.com. The titles are as follows: “Generic Revlimid Could Sink Celgene” brought out on May 16, 2018, “Celgene And Otezla Are Cracking” on May 14, 2018, “Celgene Starts the Year With a Bang” with a publish date: May 14, 2018, “Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead …” and the last “My 2 Cents On The Ozanimod Saga” with publication date: May 15, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 20 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 13, “Sell” are 0, while 7 are “Hold”. (NASDAQ:CELG) has 65% bullish analysts. 36 are the (NASDAQ:CELG)’s ratings reports on 16 May 2018 according to StockzIntelligence Inc. On Friday, April 13 the company was maintained by Morgan Stanley. In Monday, May 7 report Leerink Swann maintained it with “Buy” rating and $11500 target. On Tuesday, January 23 the rating was maintained by RBC Capital Markets with “Buy”. On Wednesday, April 4 the stock has “Buy” rating by RBC Capital Markets. The company rating was downgraded by Bank of America on Friday, January 5. On Friday, December 8 the firm has “Overweight” rating by Atlantic Securities given. In Monday, January 8 report Stifel Nicolaus maintained it with “Buy” rating and $130.0 target. In Wednesday, February 28 report Stifel Nicolaus maintained the stock with “Buy” rating. On Wednesday, December 27 the stock has “Market Perform” rating by Bernstein. On Wednesday, February 28 the rating was downgraded by SunTrust to “Hold”.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: